Reply to M. Hertzberg et al
- PMID: 32931397
- PMCID: PMC7605395
- DOI: 10.1200/JCO.20.02290
Reply to M. Hertzberg et al
Comment on
-
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.J Clin Oncol. 2020 Aug 1;38(22):2519-2529. doi: 10.1200/JCO.20.00303. Epub 2020 May 26. J Clin Oncol. 2020. PMID: 32453640 Free PMC article.
-
DA-EPOCH-R in Burkitt Lymphoma: Is It Enough for High-Risk Disease?J Clin Oncol. 2020 Nov 1;38(31):3722-3723. doi: 10.1200/JCO.20.01850. Epub 2020 Sep 15. J Clin Oncol. 2020. PMID: 32931401 No abstract available.
References
-
- Hertzberg M, Joske DJL, Gandhi MK. DA-EPOCH-R in Burkitt lymphoma: Is it enough for high-risk disease? J Clin Oncol. 2020;38:3722–3723. - PubMed
-
- Swerdlow S, Campo E, Harris N, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Volume 2 (revised ed 4). Lyon, France, IARC, 2017.
-
- The Non-Hodgkin’s Lymphoma Classification Project A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood. 1997;89:3909–3918. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
